November 2021


In 2021, InnoMedica has made important progress both with Talidox in oncology and with Talineuren in …

Read more

Mai 2021

Interview mit Prof. Dr. Smita Saxena zu Talineuren bei ALS

The application for the first clinical trial with Talineuren, InnoMedica’s drug in the field of neurology, …

Read more

May 2021

Talineuren: Clinical trial application submitted

InnoMedica has reached an important milestone with the submission of the first Clinical Trial Application for …

Read more

March 2021

ODD for Talineuren and capital increase 2021

Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) approved InnoMedica’s …

Read more

February 2021


InnoMedica is close to submission of the marketing authorization application for Talidox and plans to conduct …

Read more

December 2020

December-Update 2020

In 2020, the InnoMedica team, now counting 39 employees, was able to reach important milestones. The …

Read more

October 2020


As a result of the successful financing round of CHF 10 million in April 2020, the …

Read more

April 2020

Capital increase with public offering

Capital volume CHF 27.1 million Number of shares 1,000,000 new bearer shares with nominal value CHF …

Read more

March 2020

InnoMedica launches project for corona vaccination

The corona pandemic is a major challenge for everyone. In this context, InnoMedica can contribute its …

Read more

June 2019

Annual general meeting 2019

The Board of InnoMedica invites all shareholders to attend the Annual General Meeting 2019. The Annual General Meeting …

Read more

May 2019

Talidox better tolerated than expected

On May 14, 2019, the sixth patient was treated with Talidox at the Inselspital Bern. The …

Read more